FATE Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 5, 2026, 4:11 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Termination of a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedFate Therapeutics Enters $100.0 Million At-the-Market Stock Sale Agreement With Leerink Partners, Terminates Jefferies ATM
8-KNov. 5, 2026, 7:04 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedFate Therapeutics Q3 2026 EPS of -$0.25 Beats $0.26 Loss Estimate, but Revenue Falls to Zero; Cash Declines to $139.1 Million
8-KSept. 28, 2026, 8:10 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 13, 2026, 8:31 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits